The combination of biotechnology, biomarkers and clinical research is driving a new era in Multiple Sclerosis

Multiple sclerosis (MS) is a chronic, autoimmune, neurodegenerative neurological disease that affects the central nervous system and whose progression varies significantly from one patient to another. In Spain, an estimated 55,000 people are living with the disease, with thousands of new diagnoses each year, particularly among young adults and with a higher prevalence among women. Despite significant therapeutic advances over recent decades, important unmet medical needs remain, especially in progressive forms of the disease and in controlling disability progression.

In this context, biotechnology is redefining the approach to multiple sclerosis through new therapeutic tools, a more precise understanding of the immunological mechanisms involved, and strategies aimed not only at controlling relapses but also at slowing neurological damage progression. Sanofi, a member company of AseBio, has made this area a strategic focus within neuroscience, with research particularly centered on chronic neuroinflammation and its role in disease progression, seeking new ways to improve patients’ quality of life.

“We are increasingly gaining a better understanding of the biological mechanisms involved in disease progression and how certain processes may contribute to neurological deterioration beyond visible clinical activity,” explain Sanofi representatives in an interview conducted by AseBio on the occasion of World Multiple Sclerosis Day, celebrated on May 30. This shift is driving “a paradigm change towards a more precise, personalized approach focused on preserving neurological function and long-term quality of life.”

One of the main challenges remains the silent progression of disability. “Part of the disability associated with the disease can progress silently, representing one of the greatest unmet medical needs, especially in the progressive stages,” they note. They also warn that this progression “is not always easy to identify in its early stages,” reinforcing the need to develop tools that improve understanding of each patient’s disease course and support more precise clinical decision-making.

In this scenario, neuroinflammation has become one of the key priorities in research. According to Sanofi, this approach means “broadening the way we understand the disease.” Traditionally, therapeutic strategies have focused largely on peripheral inflammation and the control of visible relapses. However, it is now known that “processes within the central nervous system itself can contribute to neurological damage and disability progression even in the absence of relapses.”

Biotechnology is playing a crucial role in this transformation. “Thanks to the development of biomarkers, advanced neuroimaging techniques and new data analysis capabilities, it is now possible to detect changes associated with disease progression more sensitively and monitor each patient more accurately,” they explain.

These advances are paving the way for more targeted and individualized approaches. In fact, the company emphasizes that “one of the most promising developments will be the ability to use tools that enable more precise monitoring and support increasingly individualized clinical decision-making.”

Spain also holds a prominent position in this field. According to Sanofi, the country has “leading neurologists and hospitals with extensive experience in multiple sclerosis and very active participation in international clinical research.” In recent years, Spain has played a particularly significant role in clinical research in multiple sclerosis, with hundreds of patients enrolled in Phase III trials and more than one hundred centers involved.

The company believes that collaboration among hospitals, researchers, patient associations and industry is proving essential to advancing knowledge of complex diseases such as multiple sclerosis and strengthening Spain’s research capabilities.

However, significant challenges remain in accelerating patients’ access to innovation. “One of the main challenges continues to be reducing the time between scientific advances and their effective arrival to patients,” Sanofi points out. This is compounded by an increasingly competitive biomedical research environment, where Europe has lost relative weight in global clinical research over the past decade.

For this reason, the company considers it a priority to maintain an attractive environment for clinical research that continues to attract investment, participate in international studies and facilitate early access to therapeutic innovation.

Looking ahead, the future of multiple sclerosis management will involve increasingly personalized medicine based on more precise disease monitoring. “The combination of biotechnology, plasma biomarkers, advanced neuroimaging and new analytical tools will continue to advance more comprehensive monitoring and a better understanding of the mechanisms involved in disease progression,” they explain.
All of this serves a clear ultimate goal: “to help people living with multiple sclerosis maintain their autonomy, capabilities and life projects for longer.”